Literature DB >> 9620663

Gammadelta T cells present antigen to CD4+ alphabeta T cells.

R A Collins1, D Werling, S E Duggan, A P Bland, K R Parsons, C J Howard.   

Abstract

Gammadelta and alphabeta TCR+ T cells share many properties and their interactions are likely to be coordinated and regulated. We provide evidence that cattle gammadelta T cells are able to present antigen to CD4+ T cells. To help elucidate their function gammadelta T cell lines were propagated for extensive characterization. Cells expressed high levels of MHC class II and production of co-stimulatory molecules as evidenced by the binding of a CTLA-4 fusion protein and synthesis of CD80 transcripts. These properties and the presence of a well-developed endosomal compartment indicated the cells might function as antigen-presenting cells. Resting CD4+ T cells from calves immunized with ovalbumin or respiratory syncytial virus-antigen proliferated in response to gammadelta T cells pulsed with antigen that appeared to be endocytosed via clathrin-coated pits or specific receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620663     DOI: 10.1002/jlb.63.6.707

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  29 in total

1.  Subset-specific reductions in lung lymphocyte accumulation following intratracheal antigen challenge in endothelial selectin-deficient mice.

Authors:  Jeffrey L Curtis; Joanne Sonstein; Ronald A Craig; Jill C Todt; Randall N Knibbs; Timothy Polak; Daniel C Bullard; Lloyd M Stoolman
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

2.  Gut T cell receptor-γδ(+) intraepithelial lymphocytes are activated selectively by cholera toxin to break oral tolerance in mice.

Authors:  C P Frossard; K E Asigbetse; D Burger; P A Eigenmann
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

3.  Efficacy of toltrazuril 5 % suspension against Eimeria bovis and Eimeria zuernii in calves and observations on the associated immunopathology.

Authors:  Nicholas N Jonsson; Emily K Piper; Christian P Gray; Abdulkerim Deniz; Constantin C Constantinoiu
Journal:  Parasitol Res       Date:  2011-08       Impact factor: 2.289

Review 4.  γδ T-APCs: a novel tool for immunotherapy?

Authors:  Bernhard Moser; Matthias Eberl
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

Review 5.  Analysis of gamma delta T cell functions in the mouse.

Authors:  Willi K Born; Zhinan Yin; Youn-Soo Hahn; Deming Sun; Rebecca L O'Brien
Journal:  J Immunol       Date:  2010-04-15       Impact factor: 5.422

6.  Decreased expression of FcgammaRIII (CD16) by gammadelta T cells in patients with rheumatoid arthritis.

Authors:  M D Bodman-Smith; A Anand; V Durand; P Y Youinou; P M Lydyard
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

7.  gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.

Authors:  P Lundberg; G A Splitter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Selective recruitment of T-cell subsets to the udder during staphylococcal and streptococcal mastitis: analysis of lymphocyte subsets and adhesion molecule expression.

Authors:  J Soltys; M T Quinn
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

9.  Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.

Authors:  Marlène Brandes; Katharina Willimann; Gilles Bioley; Nicole Lévy; Matthias Eberl; Ming Luo; Robert Tampé; Frédéric Lévy; Pedro Romero; Bernhard Moser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

10.  Subpopulations of bovine WC1(+) gammadelta T cells rather than CD4(+)CD25(high) Foxp3(+) T cells act as immune regulatory cells ex vivo.

Authors:  Aad Hoek; Victor P M G Rutten; Jolanda Kool; Ger J A Arkesteijn; Ruth J Bouwstra; Ildiko Van Rhijn; Ad P Koets
Journal:  Vet Res       Date:  2008-10-18       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.